Veru, Inc. (VERU) Reports Q4 Loss of $0.05/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147%
December 12, 2019 6:30 AM EST--Update on Ongoing Phase 1b/2 VERU-111, Oral Selective Antitubulin, Clinical Trial Demonstrates Antitumor Activity and No Dose Related Toxicity Reached in Men with Metastatic Castration Resistant Prostate Cancer--
--VERU-111 Has Promising Signs of Progression Free Survival--Â Â Â Â Â Â Â Â Â Â Â Â Â --Advancing VERU-111 into Three Phase 2 Clinical Studies in Additional Cancer Types--Â Â Â Â Â Â --Company to Host Investor Conference Call Today at 8 a.m. ET to Discuss Financial Results and Clinical Study Data--
MIAMI, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:... More
